Juan Madoz-Gurpide
Overview
Explore the profile of Juan Madoz-Gurpide including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
993
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Luque M, Sanz-Alvarez M, Santamaria A, Zazo S, Cristobal I, de la Fuente L, et al.
Int J Mol Sci
. 2021 Dec;
22(24).
PMID: 34948097
The combination of trastuzumab plus pertuzumab plus docetaxel as a first-line therapy in patients with HER2-positive metastatic breast cancer has provided significant clinical benefits compared to trastuzumab plus docetaxel alone....
12.
Cristobal I, Santos A, Rubio J, Carames C, Zazo S, Sanz-Alvarez M, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638487
The absence of established predictive markers with value to anticipate response to neoadjuvant 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) represents a current major challenge in locally advanced rectal cancer (LARC). The tumor...
13.
Guardia C, Bianchini G, Arpi-Llucia O, Menendez S, Casadevall D, Galbardi B, et al.
Clin Cancer Res
. 2021 Aug;
27(18):5096-5108.
PMID: 34385295
Purpose: To characterize expression of neuregulin-1 (NRG1), an HER3 ligand, in HER2-positive breast cancer and its relation with the efficacy of trastuzumab with or without pertuzumab. Experimental Design: Characterization of...
14.
Sanz-Alvarez M, Martin-Aparicio E, Luque M, Zazo S, Martinez-Useros J, Eroles P, et al.
Cancers (Basel)
. 2021 Jul;
13(11).
PMID: 34204960
The use of anti-HER2 therapies has significantly improved clinical outcome in patients with HER2-positive breast cancer, yet a substantial proportion of patients acquire resistance after a period of treatment. The...
15.
Rubio J, Cristobal I, Santos A, Carames C, Luque M, Sanz-Alvarez M, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33810186
The standard treatment for patients with locally advanced colorectal cancer (LARC) is neoadjuvant 5-fluorouracil (5-FU) based chemoradiotherapy (CRT) followed by surgical mesorectal excision. However, the lack of response to this...
16.
Sanz-Alvarez M, Cristobal I, Luque M, Santos A, Zazo S, Madoz-Gurpide J, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33809005
The bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extra-terminal domain (BET) protein family, has emerged in the last years as a promising molecular target in many tumors...
17.
Cristobal I, Rubio J, Torrejon B, Santos A, Carames C, Luque M, et al.
J Clin Med
. 2020 Aug;
9(8).
PMID: 32731550
The endogenous PP2A inhibitor SET Nuclear Proto-Oncogene (SET) has been reported to play oncogenic roles and determines poor outcomes in colorectal cancer (CRC). Our group previously showed that miR-199b is...
18.
Cristobal I, Madoz-Gurpide J, Rojo F, Garcia-Foncillas J
Inflamm Bowel Dis
. 2020 Jul;
26(8):e87.
PMID: 32676641
No abstract available.
19.
Cristobal I, Rubio J, Santos A, Torrejon B, Carames C, Imedio L, et al.
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32580513
Neoadjuvant 5-fluorouracil (5-FU)-based chemoradiotherapy followed by mesorectal excision is the current standard treatment in locally advanced rectal cancer (LARC) and the lack of complete response represents a major problem that...
20.
Zazo S, Gonzalez-Alonso P, Martin-Aparicio E, Chamizo C, Luque M, Sanz-Alvarez M, et al.
Mol Cancer Ther
. 2020 May;
19(8):1696-1707.
PMID: 32404410
HER2-positive breast cancer is currently managed with chemotherapy in combination with specific anti-HER2 therapies, including trastuzumab. However, a high percentage of patients with HER2-positive tumors do not respond to trastuzumab...